Physician profile
John Charles Powers
NPI 1235199258
$9,071.81
in general payments reported to CMS, 2019-2025
25 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $1,047 · 2021: $1,517 · 2022: $3,074 · 2023: $1,167 · 2024: $806 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,743.54 | 2019-2025 | Cardiomems, Mitraclip, Amplatzer Talisman |
| Novartis Pharmaceuticals Corporation | $1,132.79 | 2019-2025 | |
| Boston Scientific Corporation | $939.73 | 2019-2025 | Watchman Access System |
| Amgen INC. | $890.63 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $813.45 | 2019-2025 | Wainua, Brilinta, Lokelma |
| Abiomed | $703.27 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $640.05 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $389.90 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $358.87 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.49 | 2019-2025 | Jardiance |
| Pfizer INC. | $185.82 | 2020-2024 | |
| Philips North America LLC | $149.13 | 2024 | (Ck4) Mcot |
| Heartflow, INC. | $149.02 | 2025 | |
| Vital Connect, INC | $126.82 | 2023-2025 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $112.52 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $68.41 | 2023-2025 | Micra, Symplicity G3 |
| Cardiva Medical, INC. | $53.80 | 2021 | |
| Biosense Webster, INC. | $42.05 | 2024-2025 | Smartablatetm System Rf Generator, Carto 3 |
| Recor Medical INC | $28.98 | 2025 | Paradise Ultrasound Renal Denervation System |
| Shockwave Medical, INC | $26.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.93 | 2023 | |
| Lantheus Medical Imaging, INC. | $19.68 | 2023 | Definity |
| Alnylam Pharmaceuticals INC. | $16.04 | 2025 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.